Announcements
- Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
- Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
- Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
- Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
- Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
More ▼
Key statistics
As of last trade, Ultragenyx Pharmaceutical Inc (UP0:FRA) traded at 36.00, 20.00% above the 52 week low of 30.00 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.00 |
---|---|
High | 36.00 |
Low | 36.00 |
Bid | 36.00 |
Offer | 36.40 |
Previous close | 37.20 |
Average volume | 3.67 |
---|---|
Shares outstanding | 83.13m |
Free float | 79.49m |
P/E (TTM) | -- |
Market cap | 3.27bn USD |
EPS (TTM) | -8.02 USD |
Data delayed at least 15 minutes, as of May 29 2024 07:00 BST.
More ▼